Diabetes, one of the most serious and common chronic diseases, is a leading cause of progressive vision loss.
1 Over 90% are individuals with type 2 diabetes mellitus (T2DM).
2 The neurovascular unit (NVU) was affected by diabetes mellitus, which is a functional unit consisting of neurons, blood vessels, and supporting cells in the central nervous system, leading to neural degeneration.
3,4 It is considered to be associated with the progression of diabetic retinopathy (DR) in the early stages of the disease. As increasing evidence of early neuronal defects prior to the onset of vascular lesions related to diabetes is found in the retina,
5–9 DR is recognized as a neurovascular complication rather than a microvascular complication of diabetes.
10 The retina has the same embryological origin and similar anatomic and physiological characteristics as the brain, so neurovascular abnormalities leading to vision loss in patients with diabetes are likely to occur in both the retina and the brain. Visual functional measurements, which reflect composite deficits along the visual pathway rather than just retinal abnormalities, can permit the identification of neurovascular damage in a subclinical stage before the recognition of DR signs. For example, visual acuity,
11 contrast sensitivity,
12,13 visual field sensitivity,
14–16 color perception,
17–20 and orientation discrimination
21 exhibit deficits even before DR. In these functional tests, the luminance-defined stimuli (first-order stimuli, such as gratings or letters) or color-defined stimuli mainly assess the visual processing at the level of the retina and primary visual cortex (V1). Evidence from brain imaging studies has shown visual functional network changes
22 and gray matter volume of occipital lobe
23 in diabetes without clinical retinopathy (NoDR). These results indicate that higher-level visual cortex areas beyond V1 may also be impaired in individuals with diabetes, both with and without retinopathy. However, it remains unclear whether there are any impairments in higher-level visual function in diabetes, especially in patients with diabetes without significant loss of visual acuity.